San Francisco Sentry Investment Group CA lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,501 shares of the biopharmaceutical company’s stock after selling 754 shares during the period. San Francisco Sentry Investment Group CA’s holdings in Gilead Sciences were worth $442,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Hall Laurie J Trustee increased its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Finally, Webster Bank N. A. increased its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. 74.04% of the stock is owned by institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 2.2969% during midday trading on Thursday, reaching $83.0958. The company’s stock had a trading volume of 16,491,139 shares. The firm has a market cap of $108.52 billion, a price-to-earnings ratio of 9.0253 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $84.13. The company has a 50-day moving average price of $72.97 and a 200-day moving average price of $68.86. Gilead Sciences also was the recipient of unusually large options trading on Monday. Stock investors bought 19,878 put options on the stock. This is an increase of 209% compared to the typical volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.08 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post $8.73 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/31/san-francisco-sentry-investment-group-ca-has-442000-position-in-gilead-sciences-inc-gild.html.

GILD has been the subject of several research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Robert W. Baird reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday. Credit Suisse Group reaffirmed an “outperform” rating and issued a $79.00 price objective on shares of Gilead Sciences in a report on Friday, May 5th. Finally, Leerink Swann reaffirmed a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. Eleven equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $81.07.

In related news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock valued at $15,223,184 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.